FORT MYERS, Fla., Oct. 2, 2025 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) Medical Director of Late Phase Clinical Research Bradley Monk, MD, Medical Director of Drug Development Manish Patel, MD and President & Managing Physician Lucio N. Gordan, MD are co-authors of an abstract aimed at educating key stakeholders about how medications used to treat cancer move from development to the clinic and the processes in place to accelerate drug discovery and regulatory ap

JERSEY CITY, N.J., Oct. 2, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions for healthcare and life sciences, has entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 812,775 of the Company's sha

SACRAMENTO, Calif. and NASHVILLE, Tenn., Oct. 2, 2025 /PRNewswire/ -- Senate Bill 39 (SB 39) for Cosmetic Safety Act was signed into law today by the Governor of California. Authored by State Sen. Akilah Weber Pierson, M.D., a board-certified OB-GYN, the measure marks a milestone in women's access to cosmetic products including a lengthy period of exemption for boric acid suppositories from the state's broader chemical ban. For a decade, pH-D Feminine Health raised awareness of the utility of bo

CMS finalized guidance this week that could delay Medicare negotiations for blockbuster drugs such as Merck’s Keytruda. The guidance describes how CMS will implement the third cycle of Medicare drug price negotiations, including how it will expand protections for certain orphan drugs in accordance with President Donald Trump’s recently enacted tax and spending package. The move is a win for the pharmaceutical industry, which has lobbied for those extra protections. But Anna Kaltenboeck, who co-a

Amgen only teased the top-line readout in its announcement, noting that it plans to present full results from the Vesalius-CV study at the American Heart Association's meeting in November. On the heels of an FDA label expansion in August, Amgen is touting another potential avenue to extend the value of its decade-old PCSK9 cholesterol med Repatha.In the late-stage Vesalius-CV study, Repatha (evolocumab) helped significantly curb the risk of major adverse cardiovascular events (MACE) over

An agreement with the FDA will see Vanda Pharmaceuticals pause or dismiss several of its lawsuits against the agency. Vanda Pharmaceuticals and the FDA have agreed to lay down their swords, squashing years of legal disputes with an agreement that will see regulatory action on much of Vanda’s grievances.The “collaborative framework” comes after Vanda chalked up a win against the agency in an August D.C. appeals court decision. After the company took its fight to market its sleep disorder

Non-balloon catheter observed zero UTIs in a 50-patient study at the University of South Florida; >500,000 uses worldwide; company selectively finalizing distributor partnerships and scaling manufacturing to meet demand LARGO, Fla., Oct. 2, 2025 /PRNewswire/ -- Lotus Medical Technologies LLC today announced the next phase of global expansion for the Lotus® Catheter, an FDA-cleared urinary catheter that replaces the traditional Foley balloon with soft, collapsible wings engineered to minimize

Following years of legal wrangling with the FDA, Vanda Pharmaceuticals has agreed to withdraw or pause several lawsuits it filed against the agency in exchange for re-reviews of two of its potential treatments for motion sickness and jet lag. Vanda said Wednesday that it will drop a lawsuit challenging the FDA’s partial clinical hold on long-term studies of tradipitant, intended for the treatment of motion sickness, after the FDA agreed to an expedited a re-review of the hold by Nov. 26. The FDA

Coinciding with 2025 American Academy of Ophthalmology Annual Meeting, the company debuts expanded services and tools for exclusive real-world insights from 85 million+ de-identified patients SAN FRANCISCO, Oct. 2, 2025 /PRNewswire/ -- Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), revealed several new enhancements to data and software solutions designed to enhance real-world insights and expedite treatment

The grants will drive research and development programs in regenerative medicine across Maryland COLUMBIA, Md., Oct. 2, 2025 /PRNewswire/ -- The Maryland Stem Cell Research Commission (the Commission) awarded $4,707,142 in grant funding to accelerate the development of innovative stem cell–based therapies. The Maryland Stem Cell Research Fund (MSCRF), overseen by the Commission, is an independent program within TEDCO designed to promote human stem cell research and treatments through grants to